POLBF (Poolbeg Pharma) Minority Interest: $0.00 Mil (As of Dec. 2025)


What is Poolbeg Pharma Minority Interest?

Poolbeg Pharma POLBF Minority Interest is $0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Poolbeg Pharma's minority interest for the quarter that ended in Dec. 2025 was $0.00 Mil.

Poolbeg Pharma Minority Interest Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma Minority Interest Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Minority Interest
0.00 0.00 0.00 0.00 0.00

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Minority Interest Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Poolbeg Pharma Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Frequently Asked Questions Learn more about Minority Interest →
What does a Minority Interest of $0.00 Mil mean?
Poolbeg Pharma (POLBF) has a Minority Interest of $0.00 Mil as of Dec. 2025. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Poolbeg Pharma.
Is Poolbeg Pharma's Minority Interest too high?
Poolbeg Pharma's current Minority Interest is $0.00 Mil.
How does Poolbeg Pharma's Minority Interest compare to VRTX and REGN?
Poolbeg Pharma's Minority Interest of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Minority Interest for a Biotechnology company?
A good Minority Interest depends on the Biotechnology industry context. However, Minority Interest should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Minority Interest mean?
A high Minority Interest can signal that a stock is expensive relative to its fundamentals. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Poolbeg Pharma. Poolbeg Pharma's current Minority Interest is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Minority Interest of $0.00 Mil. The current Minority Interest is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Minority Interest calculated?
Minority Interest is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Minority Interest is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.